TMAO, derived from dietary choline and carnitine by gut microbiota, has been shown to aggravate hepatic steatosis and fibrosis by influencing bile acid metabolism and farnesoid X receptor (FXR) signaling [91,92]. The gene discussed is NR1H4; the disease is fatty liver disease.